Portage Biotech Inc.
Portage is a unique entity in the world of biotechnology, enabling research and development to produce more clinical programs and maximize potential returns by eliminating typical overhead costs associated with many biotechnology companies. We nurture the creation of early- to mid-stage, first- and best-in-class therapies for a variety of cancers, by providing funding, strategic business and clinical counsel, and shared services, to enable efficient, turnkey execution of commercially-informed development plans. Our portfolio encompasses nine subsidiary companies whose products or technologies have established scientific rationales, including intratumorals, nanoparticles, liposomes, aptamers, cell penetrating peptides, and virus-like particles. In collaboration with our subsidiaries, we create viable product development strategies, to cost-effectively deliver best-in-class R&D, clinical trial design, and financial and project management, to ultimately build value and support commercial potential.
Portage Biotech Inc. (PBT.U)
Le 3 juin/June 2020
Portage Biotech Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidation common shares for one hundred (100) pre-consolidation common shares.
As a result, the outstanding shares of the company will be reduced to approximately 10,987,707 common shares.
The name and symbol will not change.